Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P150048/S100

INSPIRIS RESILIA Aortic Valve; MITRIS RESILIA Mitral Valve

Edwards Lifesciences, LLC · Decision date Oct 22, 2026

MEDTECHLEDGER EXPLANATIONP150048/S100

What did the FDA approve?

The FDA record identifies this as supplement P150048/S100 to Edwards Lifesciences' PMA P150048, filed under the Normal 180 Day Track No User Fee pathway with the reason "Location Change - Manufacturer/Sterilizer/Packager/Supplier." The decision, dated 2026-10-22, is APPR. The listed products are the INSPIRIS RESILIA Aortic Valve and MITRIS RESILIA Mitral Valve, non-allograft tissue heart valves under product code LWR in Cardiovascular.

The stated purpose is approval of a manufacturing site at CENTERPIECE, Bulevar La Encantada Industrial, Parque Industrial El Floride, Seccion La Encantada # 11530, Tijuana Baja California, Mexico 22250, for terminal ethylene oxide sterilization. That is a sterilization-site change within the existing PMA, not an approval of the whole valve system and not an original PMA. The record gives no sterilization cycle parameters, no validation data and no clinical or safety conclusions; the reported purpose should not be read as independent evidence of safety or effectiveness.

FDA approval order statement

approval for a manufacturing site located at CENTERPIECE (Bulevar La Encantada Industrial, Parque Industrial El Floride, Seccion La Encantada # 11530, Tijuana Baja California, Mexico 22250) for terminal ethylene oxide sterilization.
Regulatory pathway
PMA supplement
Supplement type
Normal 180 Day Track No User Fee
Clinical specialty
Cardiovascular
Decision date
Oct 22, 2026
FDA change category
Location Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P150048/S100
Regulatory pathway
PMA supplement
Product code
LWR
Decision code
APPR
Decision date
Oct 22, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: heart-valve, non-allograft tissue.

Product code
LWR
FDA device class
3

For the original device and its historical approval scope, see PMA P150048. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P150048 · Original PMA

    EDWARDS PERICARDIAL AORTIC BIOPROSTHESIS (MODEL 11000A) and EDWARDS INSPIRIS RESILIA AORTIC VALVE (MODEL 11500)

  2. P150048/S100 received

    Application receipt date recorded by FDA.

  3. P150048/S100 · FDA decision

    Normal 180 Day Track No User Fee

  4. P150048/S104 · Related supplement

    INSPIRIS RESILIA Aortic Valve (11500A), KONECT RESILIA Aortic Valve Conduit (AVC) (11060A), MITRIS RESILIA Mitral Valv

Timeline entries are records held by MedtechLedger for P150048. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P150048

Explore the linked device profile

Other records with product code LWR

Product / regulatory recordCompanyPathwayDecision dateSource
Edwards Lifesciences, LLCPMA supplementOct 28, 2026FDA
ABBOTT MEDICALPMA supplementSep 18, 2026FDA
Edwards Lifesciences, LLCPMA approvalAug 12, 2016FDA
ABBOTT MEDICALPMA approvalAug 5, 2005FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Edwards Lifesciences, LLC

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
One Edwards Way, Irvine, CA, 92614

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records